Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction

Patent metadata

Field	Value
Publication number	US-2022040174-A9
Application number	US-201916549226-A
Country	US
Kind code	A9
Filing date	Aug 23, 2019
Priority date	Nov 7, 2011
Publication date	Feb 10, 2022
Grant date	—

Abstract

The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.

First claim

What is claimed:

1 . A method of treating hot flashes in a subject diagnosed with cancer, the method comprising administering to the subject a compound of formula (I)

or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein
each K is independently N or CH, wherein at least two K′s are N;
Q, T, U, and V are independently selected from H or R;
W, X, Y and Z are independently selected from H, R, F, Cl, Br, I, OH, OR or CO 2 H;
each R is independently selected from straight chain or branched alkyl groups;
R 1 and R 2 are independently H or R; and
R 3 , R 4 , R 5 and R 6 are independently selected from H or R, thereby treating hot flashes in the subject.

2 . A method of claim 1 , wherein the subject is diagnosed with breast cancer.

3 . A method of claim 1 , wherein the subject is diagnosed with prostate cancer.

4 . A method of claim 1 , wherein the subject is diagnosed with testicular cancer.

5 . A method of claim 1 , wherein the subject is diagnosed with thyroid cancer.

6 . A method of claim 1 , wherein the subject is diagnosed with uterine cancer.

7 . A method of claim 1 , wherein the subject is diagnosed with adrenocortical carcinoma.

8 . A method of claim 1 , wherein the subject is diagnosed with a pituitary tumour.

9 . A method of claim 1 , wherein the subject is diagnosed with a tumour of the endocrine glands.

10 . A method of claim 1 , wherein the subject is diagnosed with a tumour of the hypothalamus.

11 . A method of claim 1 , wherein the subject is receiving or has received chemotherapy.

12 . A method of claim 2 , wherein the compound is administered concomitant with chemotherapy.

13 . A method of claim 2 , wherein the compound is administered after chemotherapy.

14 . A method of claim 2 , wherein the compound is administered prior to chemotherapy.

15 . A method of claim 2 , wherein administration of the compound is maintained after cessation of the chemotherapy.

16 . A method of claim 14 , wherein the subject is due to receive chemotherapy within 10 days or less of receiving the compound.

17 . A method of claim 1 , wherein the subject is receiving or has received a hormone replacement or hormone supplement.

18 . A method of claim 1 , where the compound is administered in combination with another active agent.

19 . A method of claim 1 , wherein the compound is administered in combination with an agonist or antagonist of an estrogen receptor.

20 . A method of claim 1 , wherein the compound is administered in combination with tamoxifen.

21 . A method of claim 1 , wherein the compound is:

Assignees

• Univ Emory

Inventors

• Natchus Michael G
• Arrendale Richard
• Liotta Dennis
• Desai Ketan
• Shim Hyunsuk

Classifications

• C07D403/12

  linked by a chain containing hetero atoms as chain links · CPC title

• A61K31/575

  substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol · CPC title

• A61K31/444

  containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone · CPC title

• A61K31/58

  containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048}) · CPC title

• C07C279/04

  having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton · CPC title